In breast cancer, primary HCC, PDAC, colon cancer, ccRCC, and bladder cancer, RCAN1 or RCAN1.4 shows considerably low levels of expression in cancer tissues and results in a poorer prognosis (Jin et al. 2017; Lao et al. 2021; Deng et al. 2020) (Sebio et al. 2015) (Song et al. 2018; Eissa et al. 2019). Here, RCAN1 is linked to hepatocellular carcinoma.